MedTrace Logo

Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19

NCT04362189 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2025-09-26

Study results available
· View outcomes & findings →

Summary

Hope Biosciences is conducting a research study of an investigational product called allogeneic adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) as treatment for patients suspected to have COVID-19. The study purpose is to evaluate the safety and efficacy of four IV infusions of either placebo or HB-adMSCs in subjects with COVID-19.

Conditions

Interventions

BIOLOGICAL

HB-adMSC

Hope Biosciences allogeneic adipose-derived mesenchymal stem cells

OTHER

Placebo

Saline

Sponsors & Collaborators

  • River Oaks Hospital and Clinics

    collaborator OTHER

  • United Memorial Medical Center

    collaborator OTHER

  • Hope Biosciences Research Foundation

    lead INDUSTRY

Principal Investigators

  • Rajiv Thakur, MD · River Oaks Hospital and Clinics

  • Joseph Gathe, MD · United Memorial Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-30
Primary Completion
2021-09-30
Completion
2021-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04362189 on ClinicalTrials.gov